CVE:RX - Biosyent Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$9.60 +0.05 (+0.52 %)
(As of 07/15/2018 04:00 PM ET)
Previous CloseC$9.60
Today's RangeC$9.59 - C$9.60
52-Week RangeC$8.00 - C$11.00
Volume500 shs
Average Volume8,106 shs
Market CapitalizationC$139.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used in agriculture. BioSyent Inc. distributes its products to pharmacies and hospitals. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Toronto, Canada.

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange CVE
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolCVE:RX
CUSIPN/A
Phone+1-905-2060013

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins23.96%
Return on Equity25.90%
Return on Assets23.21%

Miscellaneous

EmployeesN/A
Outstanding Shares14,509,000
Market CapC$139.88

The Truth About Cryptocurrencies

Biosyent (CVE:RX) Frequently Asked Questions

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) posted its earnings results on Wednesday, May, 30th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.01. The company had revenue of $4.45 million for the quarter. Biosyent had a return on equity of 25.90% and a net margin of 23.96%. View Biosyent's Earnings History.

When is Biosyent's next earnings date?

Biosyent is scheduled to release their next quarterly earnings announcement on Wednesday, August, 15th 2018. View Earnings Estimates for Biosyent.

What price target have analysts set for RX?

2 Wall Street analysts have issued 1-year price objectives for Biosyent's stock. Their predictions range from C$12.50 to C$12.50. On average, they anticipate Biosyent's share price to reach C$12.50 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View Analyst Ratings for Biosyent.

What is the consensus analysts' recommendation for Biosyent?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biosyent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Biosyent's key competitors?

Who are Biosyent's key executives?

Biosyent's management team includes the folowing people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Alfred D'Souza, CFO & VP of Fin.
  • Mr. Kevin Wilson, VP of Community Health Bus.
  • Mr. Sharan Raghubir MBA, Director of the Hospital Bus. Unit - Biosyent Pharma Inc
  • Mr. Peter John Weiler M.Sc., M.B.A, VP of Bus. Devel.

Has Biosyent been receiving favorable news coverage?

News stories about RX stock have been trending positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biosyent earned a daily sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the company an impact score of 45.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Biosyent?

Shares of RX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Biosyent's stock price today?

One share of RX stock can currently be purchased for approximately C$9.60.

How big of a company is Biosyent?

Biosyent has a market capitalization of C$139.88 million.

How can I contact Biosyent?

Biosyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.


MarketBeat Community Rating for Biosyent (CVE RX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe RX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.